^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2022
    Title:

    UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).

    Published date:
    05/12/2022
    Excerpt:
    All pts underwent induction therapy with intravenous administration of CPX-351...Regarding subgroup analysis by driving mutations, the 4 IDH1 pts obtained a CR...CPX-351 is active in young pts with t-AML and AML-MRC with an ORR higher than that reported in the pivotal study (78% vs 47%)...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

    Published date:
    10/01/2018
    Excerpt:
    Although subgroup size is small, all patients (100%) with IDH1/2 or NPM1 mutations were responders to CPX-351 (n=12; p<0.001 for IDH1/2 and n=6; p=0.03 for NPM1).
    DOI:
    10.1182/blood-2018-99-117412